Veracyte - About the company
Veracyte is a public company based in San Francisco (United States), founded in 2008. It operates as a Developer of genomics-based diagnostics for cancer. Veracyte has raised $67.9M in funding from General Electric and Domain Associates. The company has 459 active competitors, including 133 funded and 102 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.
Company Details
Developer of genomics-based diagnostics for cancer. The company's products include the Percepta test which is used to analyze genomic alterations within epithelial cells that line the bronchial pathway to assess a patient’s risk of lung cancer and the Afirma Thyroid FNA Analysis test is used to identify benign tumor nodules. It is also developing diagnostic tests for Idiopathic Pulmonary Fibrosis(IPF) known as the Envisia classifier.
- Website
- veracyte.com
- Social
Key Metrics
Founded Year
2008
Location
San Francisco, United States
Stage
Public
Total Funding
$67.9M in 6 rounds
Latest Funding Round
Investors
Ranked
16th among 459 active competitors
Annual Revenue
$500M - $1B as on Dec 31, 2025
Employee Count
702 as on May 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Veracyte
Veracyte is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Veracyte Inc. CIN: 146286091 , United States, Active | Jul 30, 2018 | - | - | - |
Veracyte, Inc. CIN: 20-5455398 , Belgium, Active | Dec 31, 2007 | - | 761 (As on Dec 31, 2021) | - |
Veracyte, Inc. CIN: 1384101 , United States, Active | Dec 05, 2006 | $500M - $1B (As on Dec 31, 2025) | 815 (As on Dec 31, 2023) | - |
Veracyte's IPO details
Veracyte got listed on Oct 30, 2013.
Click here to take a look at Veracyte's IPO in detail
Sign up to download Veracyte's company profile
Veracyte's funding and investors
Veracyte has raised a total funding of $67.9M over 6 rounds. Its first funding round was on 2008. Veracyte has 13 institutional investors.
Here is the list of recent funding rounds of Veracyte:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 28, 2016 | 6569089 | Conventional Debt | 1867067 | 1950180 | 9113308 | 7329773 |
Apr 23, 2015 | 3297348 | Post IPO | 8893532 | 9641082 | 1554036 | |
Sep 16, 2014 | 6857351 | Post IPO | 1472337 | 7929773 | 4304967 | 1426340 |
Access funding benchmarks and valuations. Sign up today!View details of Veracyte's funding rounds and investors
Veracyte's founders and board of directors
Founder? Claim ProfileVeracyte's employee count trend
Veracyte has 702 employees as of May 26. Here is Veracyte's employee count trend over the years:
Uncover Veracyte's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Veracyte's Competitors and alternates
Top competitors of Veracyte include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Veracyte, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 72/100 | |
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 71/100 | |
5th | Exact Sciences 1995, Madison (United States), Acquired | Provider of non-invasive molecular diagnostic testing solutions for cancer | - | 71/100 | |
6th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 70/100 | |
7th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 70/100 | ||
8th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
9th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 68/100 | |
10th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
16th | Veracyte 2008, San Francisco (United States), Public | Developer of genomics-based diagnostics for cancer | $67.9M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Veracyte's competitors? Click here to see the top ones
Veracyte's Investments and acquisitions
Veracyte has acquired 2 companies including C2i Genomics and Allegro Diagnostics. Veracyte has not made any investments as of now.See all acquisitions by Veracyte
Reports related to Veracyte
Here is the latest report on Veracyte's geography:
News related to Veracyte
Filter this listMedia has covered Veracyte for a total of 35 events in the last 1 year, 27 of them have been about company updates and 2 about people movement.
•
•
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.Business Wire•Jun 01, 2026•Veracyte
•
William Blair Investment Management Buys 112,516 Shares of Veracyte, Inc.MarketBeat•May 25, 2026•William Blair, Veracyte
•
Insider Sell: Robert Epstein Sells 10,000 Shares of Veracyte Inc (VCYT)GuruFocus•May 23, 2026•Veracyte
•
•
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder CancerBusiness Wire•May 15, 2026•Veracyte
•
•
Veracyte Presents New Data on Decipher Portfolio for Urologic Cancers at AUA 2026Business Wire•Apr 28, 2026•Veracyte
•
Veracyte Names Kevin Haas as Chief Development and Technology OfficerBusiness Wire•Mar 16, 2026•Veracyte
•
Veracyte, Inc. $VCYT Shares Acquired by ARK Investment Management LLCMarketBeat•Mar 05, 2026•ARK Investment Management, Veracyte, GW&K
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Veracyte
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
